Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jun 29;9(2):E260-7.
doi: 10.1208/aapsj0902029.

Appropriate calibration curve fitting in ligand binding assays

Affiliations

Appropriate calibration curve fitting in ligand binding assays

John W A Findlay et al. AAPS J. .

Abstract

Calibration curves for ligand binding assays are generally characterized by a nonlinear relationship between the mean response and the analyte concentration. Typically, the response exhibits a sigmoidal relationship with concentration. The currently accepted reference model for these calibration curves is the 4-parameter logistic (4-PL) model, which optimizes accuracy and precision over the maximum usable calibration range. Incorporation of weighting into the model requires additional effort but generally results in improved calibration curve performance. For calibration curves with some asymmetry, introduction of a fifth parameter (5-PL) may further improve the goodness of fit of the experimental data to the algorithm. Alternative models should be used with caution and with knowledge of the accuracy and precision performance of the model across the entire calibration range, but particularly at upper and lower analyte concentration areas, where the 4- and 5-PL algorithms generally outperform alternative models. Several assay design parameters, such as placement of calibrator concentrations across the selected range and assay layout on multiwell plates, should be considered, to enable optimal application of the 4- or 5-PL model. The fit of the experimental data to the model should be evaluated by assessment of agreement of nominal and model-predicted data for calibrators.

PubMed Disclaimer

References

    1. 2006 report, Medicines in development, biotechnology. PhRMA Website. 2006; Available at: http://www.phrma.org/files/Biotech%202006.pdf. Accessed January 14, 2007.
    1. Findlay JWA, Smith WC, Lee JW, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal. 2000;21:1249–1273. doi: 10.1016/S0731-7085(99)00244-7. - DOI - PubMed
    1. DeSilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003;20:1885–1900. doi: 10.1023/B:PHAM.0000003390.51761.3d. - DOI - PubMed
    1. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Pharm Res. 1992;9:588–592. doi: 10.1023/A:1015829422034. - DOI - PubMed
    1. Miller KJ, Bowsher RR, Celniker A, et al. Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm Res. 2001;18:1373–1383. doi: 10.1023/A:1013062600566. - DOI - PubMed

MeSH terms

LinkOut - more resources